Use of obinutuzumab in clinical practice – case report

05/2020

MUDr. Mária Maco

Interní hematologická klinika 3. LF UK a FNKV, Praha

SUMMARY

Obinutuzumab with bendamustine is currently used for the treatment of follicular lymphoma in patients who are refractory to rituximab alone or to combination of chemotherapy with rituximab. This case report describes a successful treatment with obinutuzumab and bendamustine followed by obinutuzumab maintenance in a patient with multiple relapses of follicular lymphoma after several treatment lines with rituximab.

Key words

follicular lymphoma, obinutuzumab, bendamustine, refractory lymphoma